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ABSTRACT
BD-Func (BiDirectional FUNCtional enrichment) is an algorithm that calculates
functional enrichment by comparing lists of pre-deﬁned genes that are known to be
activatedversusinhibitedinapathwayorbyaregulatorymolecule.Thispapershows
that BD-Func can correctly predict cell line alternations and patient characteristics
withaccuracycomparabletopopularalgorithms,withasigniﬁcantlyfasterrun-time.
BD-Func can compare scores for individual samples across multiple groups as well
as provide predictive statistics and receiver operating characteristic (ROC) plots to
quantify the accuracy of the signature associated with a binary phenotypic variable.
BD-Func facilitates collaboration and reproducibility by encouraging users to share
novel molecular signatures in the BD-Func discussion group, which is where the
novel progesterone receptor and LBH589 signatures from this paper can be found.
ThenovelLBH589signaturepresentedinthispaperalsoservesasacasestudyshow-
inghowacustomsignatureusingcelllinedatacanaccuratelypredictactivityin vivo.
Thissoftwareisavailabletodownloadathttps://sourceforge.net/projects/bdfunc/.
Subjects Bioinformatics, Computational Biology, Genomics
Keywords Systems biology, Functional enrichment, Pathway, Genomics, Bioinformatics,
LBH589, Gene set
INTRODUCTION
Systems-level analysis of the combined expression pattern of multiple genes can be more
informative than the expression pattern of an individual gene, and there are a number of
toolstocalculatefunctionalenrichmentofdiVerentiallyexpressedgenes(Huang,Sherman
& Lempicki, 2009; Naeem et al., 2012; Nam & Kim, 2008). However, many functional
annotationsmerelylistmembershipinapathwayorontologywithoutexplicitlymodelling
genes that should show activation or inhibition. For example, consider the KEGG
canonical Wnt signalling pathway (Fig. 1) (Kanehisa & Goto, 2000). This gene list includes
molecules that both activate and inhibit the pathway, resulting in diVerent phenotypes
(Dellinger et al., 2012; Logan & Nusse, 2004). However, many functional enrichment tools
would expect all the members of the pathway to behave similarly (Fig. 1C), such that
up-regulationofamixofactivatorsandinhibitorscanreceiveahigherscorethanselective
up-regulation of only activators within the pathway. For example, the most standard
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PeerJ1:e159; DOI10.7717/peerj.159Figure1 Manypathwaysarecharacterizedbyamixofactivationandinhibition.ThisﬁgureshowstheinitialsignallingstepsintheWntsignalling
pathway, as deﬁned by KEGG (Kanehisa & Goto, 2000). Up-regulated genes are shown in red and down-regulated genes are shown in green.
(A) Complete Activation: All genes activating the Wnt signalling pathway are up-regulated and all inhibitors are down-regulated. (B) Complete
Inhibition: All genes activating the Wnt signalling pathway are down-regulated and all inhibitors are up-regulated. (C) Mixed Pattern: All genes in
the ﬁgure are up-regulated. It is unclear what the downstream expression levels should be, but one may hypothesize a mixed result from Figs. 1A
and 1B. However, most functional enrichment tools would predict this as the pattern with the strongest up-regulation. Underneath each diagram is
the expected signal distribution that would be produced by BD-Func.
method for functional enrichment is to calculate over-representation of one gene list in
anothergenelist,possiblyusingaFisher’sexacttestorhypergeometrictest;intheexample
described above, this sort of statistical test would ask if a list of diVerentially expressed
genes shows a higher number of Wnt signalling genes than expected by chance. This sort
of test cannot diVerentiate the behavior of those genes unless more detailed gene lists
are deﬁned (such as Wnt-inhibitors versus Wnt-agonists). This is a basic problem that
BD-Func(BiDirectionalFUNCtionalenrichment)isdesignedtoovercome.
Most functional enrichment tools either require upstream ﬁltering of gene lists
(FuncAssociate (Berriz et al., 2009), GATHER (Chang & Nevins, 2006), DAVID (Huang,
Sherman & Lempicki, 2008), Connectivity Map (Lamb et al., 2006), WebGestalt
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and/or a comparison of signal intensities between two groups (T-proﬁler (Boorsma et
al., 2005), GSVA (Hanzelmann, Castelo & Guinney, 2013), PAGE (Kim & Volsky, 2005),
GSEA(Subramanianetal.,2005),ErmineJ(Leeetal.,2005)).However,BD-Funccompares
the relative expression levels between activated and inhibited genes, and we show that
BD-Func can successfully analyze either fold-change values between populations or raw
intensity/expression values (for both microarray and RNA-Seq data). Signalling Pathway
Impact Analysis (Draghici et al., 2007; Tarca et al., 2009) can be used to model activation
and inhibition within a graph, but that algorithm primarily focuses on network topology
(which is not always known); in contrast, BD-Func uses a simpler assumption of binning
genes into two categories (activation or inhibition). Additionally, the ability to analyze
absolute expression values in a single sample is a unique feature only present in a limited
number of functional genomic tools. For example, ASSESS (Edelman et al., 2006) can
theoretically predict functional enrichment in a single sample, but that score is not taken
into context amongst other samples: in other words, BD-Func uniquely uses a single
sample enrichment score as a classiﬁer, which may be useful for personalized medicine
research or for the development of novel molecular signatures where the user may need
to quantify the utility of the signature as a classiﬁer. Additionally, correlations between
a single sample and various samples within a database (such as SPIED (Williams, 2012))
can provide information about a single sample, but this requires having a database of
samplesforcomparison(so,thisstrategywillnotworkwithoutthepresenceofanexternal
database). Finally, BD-Func users are encouraged to share their lists of activated and
inhibitedgenesinasimpleﬁleformat.Thisallowseasyapplicationofmodelsthatmaynot
beinanexistingdatabaseformolecularsignatures.
This study tests the accuracy of BD-Func on datasets that were used to deﬁne gene sets
in MSigDB (Molecular Signatures DataBase, Subramanian et al., 2005), in comparison
to GSEA (Gene Set Enrichment Analysis, Mootha et al., 2003; Subramanian et al., 2005)
and IPA (Ingenuity Pathway Analysis, Ingenuity Systems, www.ingenuity.com). IPA
was selected for comparison because the upstream regulator function utilizes a similar
principleasBD-Func(activationandinhibitionispredictedbycomparingtheproportion
ofactivatedorinhibitedtargets,baseduponannotationsintheproprietaryIPAdatabase).
GSEA was selected for comparison for two reasons: (1) GSEA was speciﬁcally designed to
analyze MSigDB signatures, thus serving as a good baseline for positive control datasets
and (2) MSigDB contains some signatures for both up- and down-regulated genes,
so it is useful to compare separate analysis of these signatures (using GSEA) versus a
direct comparison of up-regulated to down-regulated gene expression (using BD-Func).
DiVerent models for TGF and progesterone receptor (PGR) activity are also tested for
robustnessbyapplicationtootherdatasets.Finally,theutilityofBD-Functostudycustom
gene signatures is tested with a novel signature associated with progesterone receptor
status in breast cancer patients as well as a novel LBH589 signature that was deﬁned using
previouslypublishedcelllinedataandisvalidatedusingnovelin vivodatapresentedinthis
study.
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BD-Func algorithm
The basic principle behind BD-Func is to treat activated and inhibited genes as replicate
observations in two populations. BD-Func is agnostic towards the type of signal used for
analysis. For example, this paper uses BD-Func to study both fold-change values between
two populations as well as raw signal intensities for a single column of signal values.
In the paper, the t-test statistic is used to compare the expression patterns of activated
and inhibited genes. However, BD-Func also allows users to compare the activated and
inhibiteddistributionsusingaMann–WhitneyUtestorKolmogorov–Smirnov(K–S)test.
BD-FuncusershavetheoptiontocalculateFalseDiscoveryRates(FDR)usingthemethod
ofBenjamini&Hochberg(1995)ortheStoreyq-value(Storey&Tibshirani,2003).
BD-Func comes with four enrichment ﬁles: c2, c5, and c6 from MSigDB (Liberzon
et al., 2011) and a list of functions deﬁned directly from the human Gene Ontology
(GO) annotations (Ashburner et al., 2000). All of these lists were created by searching for
functions with both “up” and “down” (or “positive regulation” and “negative regulation”)
gene lists. For the human GO ﬁle, a functional annotation needed to contain at least 10
positively regulated genes and 10 negatively regulated genes. We also encourage users to
share their own custom models on the BD-Func discussion group: http://sourceforge.net/
p/bdfunc/discussion/.
TherearethreediVerentinputﬁlesthatcanbeanalyzedusingBD-Func(Fig.S1):
1-D Input File: If the user supplies expression values for a single column of data, a
density plot is created for the signal for the activated and inhibited genes. In this case, the
BD-Funcalgorithmworksexactlyasdescribedabove.
2-D Input File: If the input ﬁle contains multiple columns of data, BD-Func is ﬁrst run
separately for each sample (represented by a column in the data matrix), as described
above. Next, box-plots are created for test-statistic scores for each group (labelled in the
header of the input ﬁle; Fig. S2). Finally, an ANOVA p-value is provided to compare the
teststatisticsbetweengroups.Theoretically,teststatisticscouldbeusedtomakefunctional
predictions for each sample in isolation. There are some examples in this paper where this
strategy works OK. However, comparing test statistics across all samples within diVerent
groups is the only strategy that consistently works well for all the analysis presented in this
paper.
2-D Input File for Classiﬁer: If the input ﬁle contains multiple columns of data and
two groups (called “positive” and “negative”), BD-Func will create a receiver operating
characteristic(ROC)plotusingthetest-statisticastheclassiﬁcationscoreusingtheROCR
package (Sing et al., 2005). This is in addition to all the calculations and output ﬁles for a
normal 2-D input ﬁle containing multiple columns for BD-Func to analyze (in this paper,
thisrepresentsnormalizedsignalintensityvalues).
Sample acquisition and processing
Microarray datasets were downloaded from GEO (Edgar, Domrachev & Lash, 2002) or
Array-Express (Parkinson et al., 2009). When raw CEL ﬁles were available, samples were
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for microarray analysis. Fold-Change values for all of the cell line datasets (TGF (Padua
et al., 2008; Qin et al., 2009; Renzoni et al., 2004; Sartor et al., 2010; Scandura et al., 2004),
mTOR (Wei et al., 2006), p53 (Elkon et al., 2005), and BRCA1 (Furuta et al., 2006)) and
the MSigDB progesterone receptor dataset (Claus et al., 2008) were calculated using the
methodoftheleast-squaresmeanusingPartek GenomicsSuiteTM (PartekInc,2012).
All other clinical samples (Anders et al., 2008; Bild et al., 2006; Chin et al., 2006; Finak
et al., 2008; Huang et al., 2003; Ivshina et al., 2006; Sotiriou et al., 2003; The Cancer
Genome Atlas Network, 2012) were downloaded and analyzed for diVerential expression
using BRAVO (http://bravo.coh.org/) (X Deng, C Warden, Z Liu, I Zhang, Y-C Yuan,
unpublisheddata).Thenovelprogesteronereceptorgenesignaturepresentedinthispaper
was produced by identifying genes in the expO dataset (GEO Series GSE2109) with a
jfold-changej > 2 and an False Discovery Rate (FDR)< 0.05 (where the FDR is calculated
using the method of Benjamini & Hochberg (1995) to analyze the distribution of t-test
p-values).Thisishowthesamplesinthisparticularpaperwereprocessed,butusersarenot
requiredtousethisparticularsetoftoolsforpreparingBD-Funcinputﬁlesand/orcreating
genelistsforcustomsignatures.
Reads Per Kilobase per Million mapped reads (RPKM (Mortazavi et al., 2008)) values
for RNA-Seq data was downloaded from the TCGA web portal (The Cancer Genome
Atlas Network, 2012). RPKM values were transformed by addition of 0.1 (to avoid large
fold-changevaluesforlowcoveragereads)followedbyalog2 transformation(tonormalize
thesignaldistribution).
GSEA comparison
With the exception of the progesterone receptor signature (which utilized the
CLAUS PGR POSITIVE MENINGIOMA(Clausetal.,2008)signaturefromMSigDB-c2,
version 3.1), oncogenic signatures were deﬁned using the following gene lists from
MSigDB-c6 (Liberzon et al., 2011, version 3.1) for GSEA analysis: TGFB UP.V1 (Padua
et al., 2008), MTOR UP.N4.V1 (Wei et al., 2006), P53 DN.V2 (Elkon et al., 2005),
and BRCA DN.V1 (Furuta et al., 2006). GSEA (Subramanian et al., 2005, version 2.0)
calculated p-values by permutation over phenotypes whenever possible (Anders et al.,
2008; Chin et al., 2006; Claus et al., 2008; Elkon et al., 2005; Finak et al., 2008; Huang et
al., 2003; Padua et al., 2008; Sartor et al., 2010; Scandura et al., 2004; The Cancer Genome
Atlas Network, 2012; Wei et al., 2006), although there were a few datasets with less than
3 replicates for which gene sets had to be permuted instead of phenotypes (Furuta et
al., 2006; Qin et al., 2009; Renzoni et al., 2004). For recovery of known perturbations of
oncogenic regulators, GSEA results must either show a FWER p-value < 0.25 or a NOM
p-value<0.05,whicharethedefaultcut-oVs.
IPA comparison
Ingenuity Pathway Analysis (IPA; Ingenuity Systems, www.ingenuity.com) contains an
“Upstream Regulator” module that compares the enrichment of activated and inhibited
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BD-Func except it utilizes Ingenuity’s propriety database of regulatory interactions and
uses a z-score to calculate statistical signiﬁcance between activated and inhibited genes.
GenelistsinIPAwereﬁlteredforthosegenesshowingjfold-changej > 1:5whiletheentire
gene list is used to deﬁne background enrichment. For recovery of known perturbations
of oncogenic regulators, the upstream regulator must be identiﬁed as “activated” or
“inhibited”(jz-scorej > 2),whicharethedefaultcut-oVs.
LBH589 signature
Activated and inhibited genes were deﬁned using overlapping gene lists from 3 cell line
treatments that have been previously published (Kubo et al., 2013). That same study
showed that LBH589 treatment signiﬁcantly decreased tumor volume in exemestane
(EXE) resistant MCF-7aro xenografts in mice. This study analyzes novel microarray
data from EXE-resistant tumors treated with (EXE C LBH589) or without (EXE only)
treatment of LBH589. All animal research procedures were approved by the City of Hope
Institutional Animal Care and Use Committee. This novel microarray data is available in
GEOseriesGSE47346.
In order to be included in the novel BD-Func signature, genes must show diVerential
expression in all 3 cell lines. Genes were deﬁned as diVerentially expressed if they showed
a jfold-changej > 1:5 and p-value < 0.05 , and the BD-Func signature genes had to meet
theseconditionsforeachofthe3LBH589celllinetreatments(withconsistentdirectionof
fold-change).P-valueswerecalculatedvia1-wayANOVAwithappropriatelinearcontrast
was used to compare data sets using Partek Genomics SuiteTM (Partek, Inc., St. Louis,
MO).Fold-changevalueswerecalculatedbasedupontheleast-squaresmean,anddatawas
normalizedusingrobustmultichipaverage(RMA)normalization(Irizarryetal.,2003).
RESULTS
BD-Func shows equal or greater performance to GSEA and IPA for
functional enrichment
Given the relative ease by which samples can be classiﬁed as having positive or negative
activity for an individual biomarker, the accuracy of BD-Func was ﬁrst tested by applying
several MSigDB oncogenic signatures (Liberzon et al., 2011) to the datasets from which
the signatures were deﬁned (Claus et al., 2008; Elkon et al., 2005; Furuta et al., 2006; Padua
et al., 2008; Wei et al., 2006). BD-Func was able to detect the activation or inhibition of
all of these oncogenic signatures (Table 1, Fig. 2). GSEA could detect all of the signatures
excepttheClausetal.(2008)progesteronereceptorsignature.Amongthese5testdatasets,
IPA could only detect the activity of 2 of these genes; however, this is not a completely fair
comparison because we would expect some overﬁtting of the MSigDB signatures for the
GSEAandBD-Funcanalysis.Nevertheless,thesigniﬁcanceofthisanalysisisthatBD-Func
can accurately detect perturbation of all of these biomarkers on datasets where we know
thatthesespeciﬁcgeneswillbealtered.
In order to test the performance of BD-Func, GSEA, and IPA on novel datasets (which
werenotusedbyMSigDBtodeﬁnegenelists),weappliedthe3algorithmstofourdatasets
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 6/17Figure2 BD-FuncrecoversknownMSigDBsignatures. This ﬁgure shows the output ﬁgures from BD-Func for the 5 MSigDB signatures tested on
their original datasets. (A) Density plots for fold-change values for activated genes (colored red) and inhibited genes (colored green). These plots
are used to illustrate BD-Func analysis on a single column of data (in this case, fold-change values between the positive and negative populations).
(B) Box-plots of activation versus inhibition test statistics for all relevant samples in each of the 5 MSigDB datasets. Note that each box-plot
describes the distribution of test statistics for each group – it does not represent the expression of an individual gene or a metagene. In each of these
ﬁve examples, the test statistic shows very clear diVerences among the diVerent groups. If the median t-test statistic is greater than 2, the box is
colored red. If the median t-test statistic is less than  2, the box is colored green.
with TGF treatments (Table 2). All 3 algorithms showed roughly equal performance for
predicting TGF treatment in the appropriate samples. Overall, analyses of these nine
datasetsindicatethatBD-FunccanprovidesimilarqualityresultsasGSEAandIPA.
BD-Func can determine the accuracy of novel predictive models
Sixbreastcancerdatasetswerealsousedtotesttherobustnessoftheprogesteronereceptor
(PGR)signature(Andersetal.,2008;Chinetal.,2006;Finaketal.,2008;Huangetal.,2003;
The Cancer Genome Atlas Network, 2012). Unfortunately, neither BD-Func, GSEA, nor
IPA could predict progesterone status in all seven patient populations (Table 3). To be
fair, the original Claus et al. (2008) dataset was used to deﬁne progesterone receptor status
in meningioma samples whereas the novel datasets tested were all breast cancer samples
(where testing for over-expression of progesterone receptor is common (Bardou et al.,
2003)). Nevertheless, BD-Func is designed to be able to utilize custom gene signatures
with activated and inhibited, so we deﬁned a novel progesterone receptor signature
using the expO dataset (GEO Series GSE2109). This signature can identify progesterone
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 7/17Table 1 Recovery of known perturbations for selected MSigDB oncogenic genes. BD-Func “Fold-
Change” corresponds to analysis of fold-change values calculated between the perturbed and unper-
turbed groups. BD-Func “Intensity” corresponds to calculation of activity vs. inhibition score for each
sample in the dataset followed by a comparison in the distribution of test statistics for all of the samples.
BD-Func
(Fold-change)
BD-Func
(Intensity)
GSEA IPA
TGF
(E-TABM-420)
Yes Yes Yes (UP)
Yes (DN)
Yes
mTOR – N4
(GSE5824)
Yes Yes Yes (UP)
Yes (DN)
No
P53 – V2a
(GSE1676 )
Yes Yes Yes (UP)
No (DN)
Yes
BRCA1
(GSE4754)
Yes Yes Yes (UP)
Yes (DN)
No
PGR
(GSE9438)
Yes Yes No (UP)
No (DN)
No
Notes.
a 1p53 signal changes with sign matching p53 expression (in this case P53 DN indicates genes down-regulated by
knock-down of p53, not genes negatively related by p53).
Table2 PredictionofTGF activityinnoveldatasets.
BD-Func
(Fold-change)
BD-Func
(Intensity)
GSEA IPA
GSE1724 Yes Yes Yes (UP)
No (DN)
Yes
GSE1805 No Noa No (UP)
Yes (DN)
No
GSE6653 Yes Yes Yes (UP)
Yes (DN)
Yes
GSE17708 Yes Yes Yes (UP)
No (DN)
Yes
Notes.
a Qualitatively detected at 2 h but not 4 h, but activity is not signiﬁcant with p-value < 0.05 for either time-point.
receptorpositiveandnegativepatientsforall7cohorts(1meningiomaand6breastcancer
datasets),soitisrobustenoughforapplicationtomultiplecancertypes.
Another unique feature of BD-Func is the ability to use the activation versus inhibition
teststatisticasaclassiﬁertodeﬁneapredictivemodel.Ifat-teststatisticof2isusedforthe
cut-oV of distinguishing the positive and negative populations (roughly corresponding to
a p-value < 0.05), it is clear that the MSigDB signature is extremely accurate at predicting
PGRstatusintheoriginaldatasetbutnotinthebreastcancerdatasets(TableS1).Likewise,
theTGF signaturecoulddiVerentiatebetweenthetreatedanduntreatedgroupsifthetest
statistic of 2 was used as the threshold to distinguish the groups (Fig. S2). However, this
thresholddoesnotworkwellinallcircumstances:unliketheanalysisoffold-changevalues,
the p-value (for any statistical method) is not always the ideal statistic for assessment of
functionalenrichmentonintensityvalues.Forexample,themTORandBRCA1signatures
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 8/17Table 3 Prediction of progesterone receptor status in patient samples. In this table, BD-Func is used
to analyze fold-change values between PRC and PR  patients.
Cohort BD-Func
(MSigDB)
BD-Func
(COH)
GSEA
(MSigDB)
IPA
GSE9438
(N D 31)
Yes Yes No (UP)
No (DN)
No
(Huang et al., 2003)
(N D 88)
No Yes No (UP)
No (DN)
No
(Chin et al., 2006)
(N D 117)
No Yes No (UP)
No (DN)
No
(Anders et al., 2008)
(N D 73)
No Yes No (UP)
No (DN)
No
(Finak et al., 2008)
(N D 53)
No Yes No (UP)
No (DN)
No
expO
(N D 256)
No Yes No (UP)
No (DN)
No
TCGA
(N D 739)
No Yes No (UP)
No (DN)
No
Notes.
MSigDB D CLAUS PGR POSITIVE MENINGIOMA signatures. COH D novel PGR signature developed in this
study.
(Fig. 2B) show appropriate changes in test statistics that clearly distinguish treated and
untreated groups, but activation and inhibition can’t be deﬁned based upon a pre-deﬁned
cut-oV for the test statistic value (e.g., 2 or  2). For this reason, we provide an ANOVA
p-value to quantify the diVerence in test-statistic between groups, where the test statistic
servesasascoreforasecondcalculationofstatisticalsigniﬁcance.
Additionally, we believe that predictive statistics are a useful method for accessing
BD-Func scores for individual samples within large patient populations. In order to
quantify the accuracy of the model without depending on a pre-deﬁned cut-oV, BD-Func
produces receiver operating characteristic (ROC) plots for each cohort and the area
under the curve (AUC) is calculated for each ROC plot (where a 100% accurate model
would have an AUC D 1.00) (Fig. S3, Table S1). The superior performance of the novel
PGR signature on the breast cancer cohorts becomes even clearer when these predictive
statistics are compared for the two models (Fig. 3, Fig. S4, and Table S2). Importantly, the
novel signature showed the same level of accuracy on the TCGA breast cancer dataset as
the original expO dataset. This is signiﬁcant because the TCGA dataset is over twice as
large as the expO dataset, and the TCGA dataset utilizes RNA-Seq while the expO dataset
utilizes microarrays to quantify gene expression. In other words, this shows that BD-Func
is capable of producing very robust predictions that translate across diVerent genomic
technologies.
BD-Func accurately quantiﬁes LBH589 activity using a novel sig-
nature
LBH589 (panobinostat) is a histone deacetylase inhibitor that has been previously shown
tosuppresstheproliferationofaromataseinhibitorresistantbreastcancercells,whichwas
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 9/17Figure 3 Custom progesterone signature outperforms MSigDB signature on breast cancer pa-
tients. AUC (Area Under the Curve) values from the ROC plots for each patient cohort are displayed.
Although the MSigBD gene set shows extremely high accuracy for the original meningioma dataset, it
shows essentially random predictive power for the 6 larger breast cancer datasets. On the other hand,
a custom progesterone receptor signature deﬁned using the expO dataset shows high accuracy for all 7
cohorts, and the high accuracy is maintained even in the largest cohort (TCGA).
a conclusion supported in part by functional enrichment analysis of commonly aVected
genes from 3 cell line experiments (Kubo et al., 2013). Gene lists derived from these cell
lineexperimentscanbeeasilyusedtodeﬁneaBD-Funcsignature,sowehypothesizedthat
the results from this previous in vitro cell culture study could be used to predict LBH589
activity in vivo in an animal study. Speciﬁcally, we asked if the signature deﬁned based
upon LBH589 treatment in 3 cell lines (H295R, MCF-7her2, HeLa) could detect LBH589
activity in a mouse xenograft from a diVerent cell line (MCF-7aro xenograft treated with
EXE). Indeed, BD-Func correctly used the cell line LBH589 signature to identify common
gene expression changes in the tumours treated with LBH589 and EXE compared to the
micethatwereonlyexposedtoEXEtreatment(Fig.4).
DISCUSSION
Comparison of BD-Func to GSEA indicated that BD-Func can provide similar oncogenic
signaturepredictionswithmuchshorterruntime(TableS3)andamoredirectcomparison
of genes that are expected to be up- or down-regulated by the oncogenic regulators. One
limitationtoBD-Funcisthatitcanonlyconductfunctionalenrichmentforregulatorswith
genes that are both up- and down-regulated, so there are many gene lists in MSigDB that
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 10/17Figure4 NovelcelllineLBH589signaturecanaccuratelydetectdrugactivityinvivo.(A)BD-Funcdensityplotforfold-changevaluesforactivated
and inhibited genes for Exe C LBH589 vs. Exe alone tumors. At a population level, the Exe + LBH589 tumors show higher expression of activated
genes whereas the Exe tumors show increased expression of inhibited genes (p D 2:010 15). (B) BD-Func box-plot for single-sample signature
scores. EXE alone shows the greatest inhibition of LBH-related gene expression whereas EXE C LBH shows less inhibition of LBH-related gene
expression.
cannot be analyzed using BD-Func (which instead should be analyzed using a tool such as
GSEA). It is also worth noting that BD-Func can work with a wide range of sizes of gene
listsforactivatedandinhibitedgenes(TableS4),butwewouldrecommendusingatleasta
fewdozengeneswhendeﬁningcustomsignatures.
Comparison of the BD-Func oncogenic signatures to the IPA upstream regulators also
showed that both programs could provide similar performance, which is not surprising
giving the design of that module in IPA. One beneﬁt to utilizing IPA is that IPA has a
curateddatabasewhichlistswithawidervarietyofregulatorsthantheMSigDBoncogenic
signatures that can be analyzed in BD-Func. In contrast, one major beneﬁt to using
BD-Func is the greater theoretical range of applications. For example, BD-Func provides
an enrichment ﬁle for Gene Ontology (GO) categories (Ashburner et al., 2000), but
IPA does utilize this same strategy of analyzing functional ontologies by comparing the
expressionofpositivelyandnegativelyregulatedgenes.
The Connectivity Map is a commonly used tool to study gene expression pro-
ﬁles for drugs and other chemical perturbations (Lamb et al., 2006). There are no
LBH589/panobinostat treatments in the Connectivity Map database (although this
database can certainly provide other useful information), so BD-Func provides a unique
opportunity to test for gene signatures that show a strong positive or negative correlation
with novel drug treatments (such as LBH589). Additionally, BD-Func is compatible with
any gene mapping (in this case, gene symbol), whereas the Connectivity Map requires
users to deﬁne their signatures in terms of HG-U133A probes. For example, aVected gene
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 11/17symbols had to be converted to HG-U133A probes for this analysis. We believe that being
abletodeﬁnesignaturesbasedupongenesymbolisasubstantialpracticalbeneﬁt.
BD-Func also calculates a test statistic to represent functional activation or inhibition
for each individual sample in a dataset, and this study shows how this statistic can be
directly used as a classiﬁer that can be used to quantify the predictive power of a given
functional model. More speciﬁcally, this study shows the utility of using BD-Func for
applying two novel predictive models (for progesterone receptor status in patients and for
LBH589 drug treatment). The LBH589 signature provided biological conﬁrmation that
theresultsfromanin vitromodelcanindeedapplytovalidationexperimentsin vivo.This
is important because our hope is that the streamlined analysis, simple input ﬁle design,
and BD-Func discussion board can be used to help scientists quickly and easily share
novel predictive models. In short, BD-Func provides a novel framework for functional
enrichment(bycomparingtherelativeexpressionofactivatedversusinhibitedgenes)that
is freely available with a user interface that is accessible to biologists without any coding
experience. The results of this paper show that BD-Func provides accurate predictions
matched by other popular tools, which make it a useful complement to standard analysis
usingtoolslikeGSEAorIPA.
ACKNOWLEDGEMENTS
WewouldliketothankChristineBrown,MikeBarish,andThanhDellingerfordiscussions
thatledtothecreationofthisalgorithm.WewouldliketothankXiweiWu,ZhengLiu,and
twoanonymousreviewersfordiscussionsregardingtheBD-Funcalgorithm.Wewouldlike
tothanktheCityofHopeFunctionalGenomicsCoreforprocessingthemicroarraydata.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
ThisworkwassupportedbygrantsfromtheNationalInstitutesofHealth[Comprehensive
Cancer Center Grant P30 CA33572], Susan G. Komen for the Cure [KG080161 to SC]
and City of Hope National Medical Center institutional funding. The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Grant Disclosures
Thefollowinggrantinformationwasdisclosedbytheauthors:
NIH:P30CA33572.
SusanG.KomenfortheCure:KG080161.
CityofHopeNationalMedicalCenter.
Competing Interests
Theauthorsdeclaretherearenocompetinginterests.
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 12/17Author Contributions
 Charles D. Warden conceived and designed the experiments, performed the experi-
ments,analyzedthedata,wrotethepaper,designedthealgorithm.
 Noriko Kanaya conceived and designed the experiments, performed the experiments,
contributedreagents/materials/analysistools,wrotethepaper.
 Shiuan Chen conceived and designed the experiments, contributed
reagents/materials/analysistools,wrotethepaper.
 Yate-ChingYuanconceivedanddesignedtheexperiments,wrotethepaper.
Animal Ethics
Thefollowinginformationwassuppliedrelatingtoethicalapprovals(i.e.,approvingbody
andanyreferencenumbers):
AllanimalresearchprocedureswereapprovedbytheCityofHopeInstitutionalAnimal
CareandUseCommittee.
Microarray Data Deposition
Thefollowinginformationwassuppliedregardingthedepositionofmicroarraydata:
GSE47346.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/
10.7717/peerj.159.
REFERENCES
Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y,
Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A. 2008. Age-speciﬁc
diVerences in oncogenic pathway deregulation seen in human breast tumors. PLoS ONE 3:e1373
DOI 10.1371/journal.pone.0001373.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K,
Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC,
Richardson JE, Ringwald M, Rubin GM, Sherlock G. 2000. Gene ontology: tool for the
uniﬁcation of biology. Nature Genetics 25:25–29 DOI 10.1038/75556.
Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM. 2003. Progesterone receptor
status signiﬁcantly improves outcome prediction over estrogen receptor status alone for
adjuvant endocrine therapy in two large breast cancer databases. Journal of Clinical Oncology
21:1973–1979 DOI 10.1200/JCO.2003.09.099.
Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful
approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological)
57:289–300.
Berriz GF, Beaver JE, Cenik C, Tasan M, Roth FP. 2009. Next generation software for functional
trend analysis. Bioinformatics 25:3043–3044 DOI 10.1093/bioinformatics/btp498.
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi M-B, Harpole D, Lancaster JM,
Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. 2006. Oncogenic
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 13/17pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353–357
DOI 10.1038/nature04296.
Boorsma A, Foat BC, Vis D, Klis F, Bussemaker HJ. 2005. T-proﬁler: scoring the activity of
predeﬁned groups of genes using gene expression data. Nucleic Acids Research 33:W592–W595
DOI 10.1093/nar/gki484.
Chang JT, Nevins JR. 2006. GATHER: a systems approach to interpreting genomic signatures.
Bioinformatics 22:2926–2933 DOI 10.1093/bioinformatics/btl483.
Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W-L, Lapuk A, Neve RM,
Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K,
Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. 2006.
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer
Cell 10:529–541 DOI 10.1016/j.ccr.2006.10.009.
Claus EB, Park PJ, Carroll R, Chan J, Black PM. 2008. Speciﬁc genes expressed in
association with progesterone receptors in meningioma. Cancer Research 68:314–322
DOI 10.1158/0008-5472.CAN-07-1796.
Dellinger TH, Planutis K, Jandial DD, Eskander RN, Martinez ME, Zi X, Monk BJ,
Holcombe RF. 2012. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic
clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.
Gynecologic Oncology 126:259–267 DOI 10.1016/j.ygyno.2012.04.026.
Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R. 2007.
A systems biology approach for pathway level analysis. Genome Research 17:1537–1545
DOI 10.1101/gr.6202607.
Edelman E, Porrello A, Guinney J, Balakumaran B, Bild A, Febbo PG, Mukherjee S. 2006.
Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for
individual samples in genome-wide expression proﬁles. Bioinformatics 22:e108–e116
DOI 10.1093/bioinformatics/btl231.
Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and
hybridization array data repository. Nucleic Acids Research 30:207–210
DOI 10.1093/nar/30.1.207.
Elkon R, Rashi-Elkeles S, Lerenthal Y, Linhart C, Tenne T, Amariglio N, Rechavi G, Shamir R,
Shiloh Y. 2005. Dissection of a DNA-damage-induced transcriptional network using a
combination of microarrays, RNA interference and computational promoter analysis. Genome
Biology 6:R43 DOI 10.1186/gb-2005-6-5-r43.
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G,
Meterissian S, Omeroglu A, Hallett M, Park M. 2008. Stromal gene expression predicts clinical
outcome in breast cancer. Nature Medicine 14:518–527 DOI 10.1038/nm1764.
Furuta S, Wang J-M, Wei S, Jeng Y-M, Jiang X, Gu B, Chen P-L, Lee EYHP, Lee W-H. 2006.
Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated
mammary tumor growth contributed by prominent vasculature. Cancer Cell 10:13–24
DOI 10.1016/j.ccr.2006.05.022.
Hanzelmann S, Castelo R, Guinney J. 2013. GSVA: gene set variation analysis for microarray and
RNA-Seq data. BMC Bioinformatics 14:7 DOI 10.1186/1471-2105-14-7.
Huang DW, Sherman BT, Lempicki RA. 2008. Systematic and integrative analysis of large gene
lists using DAVID bioinformatics resources. Nature Protocols 4:44–57
DOI 10.1038/nprot.2008.211.
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 14/17Huang DW, Sherman BT, Lempicki RA. 2009. Bioinformatics enrichment tools: paths toward
the comprehensive functional analysis of large gene lists. Nucleic Acids Research 37:1–13
DOI 10.1093/nar/gkn923.
Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M,
Chen CM, West M, Nevins JR, Huang AT. 2003. Gene expression predictors of breast cancer
outcomes. The Lancet 361:1590–1596 DOI 10.1016/S0140-6736(03)13308-9.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003.
Exploration, normalization, and summaries of high density oligonucleotide array probe level
data. Biostatistics 4:249–264 DOI 10.1093/biostatistics/4.2.249.
Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P,
Nordgren H, Wong JEL, Liu ET, Bergh J, Kuznetsov VA, Miller LD. 2006. Genetic
reclassiﬁcation of histologic grade delineates new clinical subtypes of breast cancer. Cancer
Research 66:10292–10301 DOI 10.1158/0008-5472.CAN-05-4414.
Kanehisa M, Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids
Research 28:27–30 DOI 10.1093/nar/28.1.27.
Kim S-Y, Volsky D. 2005. PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics
6:144 DOI 10.1186/1471-2105-6-144.
Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M,
Shimada K, Takahashi M, Chu P, Yuan Y-C, Chen S. 2013. Inhibition of the proliferation
of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase
inhibitor LBH589 (panobinostat). Breast Cancer Research and Treatment 137:93–107
DOI 10.1007/s10549-012-2332-x.
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P,
Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ,
Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. 2006. The connectivity map: using
gene-expression signatures to connect small molecules, genes, and disease. Science
313:1929–1935 DOI 10.1126/science.1132939.
Lee H, Braynen W, Keshav K, Pavlidis P. 2005. ErmineJ: tool for functional analysis of gene
expression data sets. BMC Bioinformatics 6:269 DOI 10.1186/1471-2105-6-269.
Liberzon A, Subramanian A, Pinchback R, Thorvaldsd´ ottir H, Tamayo P, Mesirov JP. 2011.
Molecular signatures database (MSigDB) 3.0. Bioinformatics 27:1739–1740
DOI 10.1093/bioinformatics/btr260.
Logan CY, Nusse R. 2004. The Wnt signaling pathway in development and disease. Annual Review
of Cell and Developmental Biology 20:781–810 DOI 10.1146/annurev.cellbio.20.010403.113126.
Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, Puigserver P,
Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP,
Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC.
2003. PGC-1-responsive genes involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nature Genetics 34:267–273 DOI 10.1038/ng1180.
Mortazavi A, Williams BA, McCue K, SchaeVer L, Wold B. 2008. Mapping and quantifying
mammalian transcriptomes by RNA-Seq. Nature Methods 5:621–628 DOI 10.1038/nmeth.1226.
Naeem H, Zimmer R, Tavakkolkhah P, K¨ uVner R. 2012. Rigorous assessment of gene set
enrichment tests. Bioinformatics 28:1480–1486 DOI 10.1093/bioinformatics/bts164.
Nam D, Kim S-Y. 2008. Gene-set approach for expression pattern analysis. Brieﬁngs in
Bioinformatics 9:189–197 DOI 10.1093/bib/bbn001.
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 15/17Padua D, Zhang XHF, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagu´ e J. 2008. TGF
primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133:66–77
DOI 10.1016/j.cell.2008.01.046.
Parkinson H, Kapushesky M, Kolesnikov N, Rustici G, Shojatalab M, Abeygunawardena N,
Berube H, Dylag M, Emam I, Farne A, Holloway E, Lukk M, Malone J, Mani R, Pilicheva E,
Rayner TF, Rezwan F, Sharma A, Williams E, Bradley XZ, Adamusiak T, Brandizi M,
Burdett T, Coulson R, Krestyaninova M, Kurnosov P, Maguire E, Neogi SG, Rocca-Serra P,
Sansone S-A, Sklyar N, Zhao M, Sarkans U, Brazma A. 2009. ArrayExpress update—from
an archive of functional genomics experiments to the atlas of gene expression. Nucleic Acids
Research 37:D868–D872 DOI 10.1093/nar/gkn889.
Partek Inc. 2012. Partek Genomics Suite, Version 6.6, revision 6.12.1011 ed. St. Louis.
Qin H, Chan M, Liyanarachchi S, Balch C, Potter D, Souriraj I, Cheng A, Agosto-Perez F,
Nikonova E, Yan P, Lin H-J, Nephew K, Saltz J, Showe L, Huang T, Davuluri R. 2009. An
integrative ChIP-chip and gene expression proﬁling to model SMAD regulatory modules.
BMC Systems Biology 3:73 DOI 10.1186/1752-0509-3-73.
Renzoni E, Abraham D, Howat S, Shi-Wen X, Sestini P, Bou-Gharios G, Wells A,
Veeraraghavan S, Nicholson A, Denton C, Leask A, Pearson J, Black C, Welsh K, du Bois R.
2004. Gene expression proﬁling reveals novel TGF targets in adult lung ﬁbroblasts. Respiratory
Research 5:24 DOI 10.1186/1465-9921-5-24.
Sartor MA, Mahavisno V, Keshamouni VG, Cavalcoli J, Wright Z, Karnovsky A, Kuick R,
Jagadish HV, Mirel B, Weymouth T, Athey B, Omenn GS. 2010. ConceptGen: a gene
set enrichment and gene set relation mapping tool. Bioinformatics 26:456–463
DOI 10.1093/bioinformatics/btp683.
Scandura JM, Boccuni P, Massagu´ e J, Nimer SD. 2004. Transforming growth factor -induced
cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proceedings
of the National Academy of Sciences of the United States of America 101:15231–15236
DOI 10.1073/pnas.0406771101.
Sing T, Sander O, Beerenwinkel N, Lengauer T. 2005. ROCR: visualizing classiﬁer performance
in R. Bioinformatics 21:3940–3941 DOI 10.1093/bioinformatics/bti623.
Sotiriou C, Neo S-Y, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL,
Liu ET. 2003. Breast cancer classiﬁcation and prognosis based on gene expression proﬁles from
a population-based study. Proceedings of the National Academy of Sciences of the United States of
America 100:10393–10398 DOI 10.1073/pnas.1732912100.
Storey JD, Tibshirani R. 2003. Statistical signiﬁcance for genomewide studies. Proceedings
of the National Academy of Sciences of the United States of America 100:9440–9445
DOI 10.1073/pnas.1530509100.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A,
Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression proﬁles. Proceedings
of the National Academy of Sciences of the United States of America 102:15545–15550
DOI 10.1073/pnas.0506580102.
Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim J-s, Kim CJ, Kusanovic JP, Romero R.
2009. A novel signaling pathway impact analysis (SPIA). Bioinformatics 25(1):75–82
DOI 10.1093/bioinformatics/btn577.
The Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast
tumours. Nature 490:61–70 DOI 10.1038/nature11412.
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 16/17Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den
Boer ML, Pieters R, Golub TR, Armstrong SA. 2006. Gene expression-based chemical
genomics identiﬁes rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer
Cell 10:331–342 DOI 10.1016/j.ccr.2006.09.006.
Williams G. 2012. A searchable cross-platform gene expression database reveals connections
between drug treatments and disease. BMC Genomics 13:12 DOI 10.1186/1471-2164-13-12.
Zeeberg B, Feng W, Wang G, Wang M, Fojo A, Sunshine M, Narasimhan S, Kane D,
Reinhold W, Lababidi S, Bussey K, Riss J, Barrett J, Weinstein J. 2003. GoMiner: a
resource for biological interpretation of genomic and proteomic data. Genome Biology
4:R28 DOI 10.1186/gb-2003-4-4-r28.
Zhang B, Kirov S, Snoddy J. 2005. WebGestalt: an integrated system for exploring gene sets in
various biological contexts. Nucleic Acids Research 33:W741–W748 DOI 10.1093/nar/gki475.
Warden et al. (2013), PeerJ, DOI 10.7717/peerj.159 17/17